March 6th 2023
Pembrolizumab also appears to garner modest anti-tumor activity regardless of PD-L1 expression in patients with advanced thyroid cancer.
CT and Ultrasonography Have Similar Diagnostic Accuracy for Papillary Thyroid Cancer Cervical Lymph Node MetastasesMarch 2nd 2022
A system review and meta-analysis found that computed tomography and ultrasonography had comparable diagnostic accuracy in identifying cervical lymph node metastases in patients with papillary thyroid cancer.
FDA Approves Cabozantinib for Radioactive Iodine–Refractory Differentiated Thyroid CancerSeptember 17th 2021
Findings from the phase 3 COSMIC-311 trial led to the approval of cabozantinib in patients with radioactive iodine–refractory locally advanced or metastatic differentiated thyroid cancer.
FDA Grants Cabozantinib Priority Review in Radioactive Iodine–Refractory Differentiated Thyroid CancerAugust 5th 2021
Based on results from the phase 3 COSMIC-311 trial, the FDA has accepted an application for cabozantinib use in patients with differentiated thyroid cancer with refractory disease following radioactive iodine therapy.
Cabozantinib Appears to be a Promising New Treatment Option in Radioiodine-Refractory Differentiated Thyroid CancerJuly 18th 2021
Results from the phase 3 COSMIC-311 trial indicated that cabozantinib elicited a promising survival benefit in patients with radioiodine-refractory differentiated thyroid cancer.
Prior Therapy Does Not Influence Selpercatinib Efficacy in RET+ Medullary Thyroid CancerJune 8th 2021
Responses to selpercatinib in patients with pretreated medullary thyroid cancer were noted irrespective of therapy regimens received in prior lines, according to data from the 2021 ASCO Annual Meeting.
Improved Overall Survival Observed With Lenvatinib for Patients With Thyroid Cancer and Lung MetastasesMay 11th 2021
Investigators observed a survival benefit for patients receiving lenvatinib who had radioiodine-refractory differentiated thyroid cancer with lung metastases of 1 cm or greater.
Study Identifies Effectiveness of RNA, DNA-RNA Tests for Diagnosis of Indeterminate Thyroid NodulesDecember 29th 2020
“Although previous trials demonstrated that the prior version of the DNA-RNA test was more specific than the prior version of the RNA test, the current molecular test techniques have no statistically significant difference in performance,” wrote Masha J. Livhits, MD, and colleagues.
Inaccurate Risk Perceptions Lead to Worry and Decreased QOL in Patients with Thyroid CancerJanuary 29th 2020
The perceptions, which were associated with worry and a decreased quality of life, indicated the need for patient education that is suitable for diverse populations and improved risk communication by physicians.
Expert Weighs In On Appropriate Evaluation After a Thyroid Cancer DiagnosisNovember 4th 2019
While there have been increases in the amount of thyroid cancer cases detected, there is still work for oncologists to do – namely to ensure there is adequate evaluation of the disease at diagnosis.
Hemithyroidectomy Rates Increase Following Guideline ChangeSeptember 9th 2019
In late 2015, the American Thyroid Association (ATA) changed guideline recommendations trying to rein in overly aggressive treatment of thyroid cancers that are low risk, offering the choice of hemithyroidectomy as an alternative to total thyroidectomy in these patients. In participating hospitals, the rates of hemithyroidectomy went up.